The role of open innovation in biomarker discovery
Journal Title: Advances in Precision Medicine - Year 2016, Vol 1, Issue 2
Abstract
Precision medicine aims to treat diseases with special consideration for the individual biological variability. Novel biomarkers (BM) are needed to predict therapeutic responses and to allow for the selection of suitable patients for treatment with certain drugs. However, the identification and validation of appropriate BMs is challenging. Close collaboration between different partners seems to be a key success factor. While the importance of partnerships and larger, well-established consortia in BM discovery such as the pharmaceutical industry and academic institutions is well understood and has been investigated in the past, the use of open-innovation models, also known as ‘crowd sourcing for biomarkers’, is still in its infancy. Crowd sourcing comprises of a — usually via internet — request for problem solution to an open group of users in a kind of an ‘open call’. The community (crowd) is asked to provide solutions. Since the application of the crowd sourcing method offers the possibility to collect as many as possible novel ideas from a broad community with different expertise, this approach is particularly promising for BM development. In this article we describe the first examples of open-innovation models, such as the ‘grants for targets’ (G4T) and biomarkers initiative ‘InnoCentive’ (innovation/incentive) platform. They may be a fruitful basis for collaborative BM development in the future.
Authors and Affiliations
Lilla Landeck, Monika Lessl, Andreas Busch, Matthias Gottwald and Khusru Asadullah
Keywords
Related Articles
- EP ID EP679273
- DOI -
- Views 168
- Downloads 0
Collaboration for success: the value of strategic collaborations for precision medicine and biomarker discovery
Precision medicine aims to provide the precise treatment for the patient with the right dose at the right point of time. Biomarkers (BM) are vital for the identification of patients who would benefit the most from indivi...
Reproducibility of preclinical data: one man's poison is another man's meat
Limited reproducibility of preclinical data is increasingly discussed in the literature. Failure of drug development programs due to lack of clinical efficacy is also of growing concern. The two phenomena may share an im...
Personalized medicine: consequences for drug research and therapy
In drug research, a serious transformation has taken place. With increasing knowledge gained from molecular medicine, it became possible to refine and develop new therapies based on the molecular mechanisms of diseases....
Success factors in drug discovery and development
The article aimed to give a personal perspective on drug discovery and development. The author has worked both in Big Pharma as a scientist and manager and more recently also in start-up biotech companies. Drug companies...
Investigating the health-economic profiles of biomarker-driven immunosuppresion (BIO-DrIM) following solid organ transplantation
Immunosuppression (IS) following solid organ transplantation is indicated to avoid rejection but puts a significant burden on patients and healthcare systems due to life-long medication dependency and associated costs. O...